Clinical Trial Update: Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab in combination with everolimus for refractory metastatic renal cell carcinoma has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: Sandy Srinivas | Conditions: Kidney Neoplasms, Kidney (Renal Cell) Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-07-29